Citations

Clear

4847 citation(s) found for "Yu, Eric".

Comparison of 2-year outcomes with CAR T cells (ZUMA-1) vs salvage chemotherapy in refractory large B-cell lymphoma
Neelapu, Sattva S. , Bartlett, Nancy L. , Lekakis, Lazaros J. , Miklos, David B. , Jacobson, Caron A. , Braunschweig, Ira , Oluwole, Olalekan O. , Siddiqi, Tanya , Lin, Yi , Crump, Michael , Neste, Eric Van Den , Farooq, Umar , Navale, Lynn, DePuy, Venita, Gisselbrecht, Christian , Bartlett, Nancy L , Miklos, David B , Oluwole, Olalekan O , Siddiqi, Tanya , Farooq, Umar , Lin, Yi , Locke, Frederick L. , Reagan, Patrick Michael , Kuruvilla, John , Kim, Jaeyeon

Mayo Clinic

Blood Advances | September 3, 2021 | Volume: 5 | Issue: 20 | Pages: 4149-4155

10.1182/bloodadvances.2020003848 | PMID 34478487 Get It

Abstract The SCHOLAR-1 international retrospective study highlighted poor clinical outcomes and survival among patients with refractory large B-cell lymphoma (LBCL) treated with conventional chemotherapy. Axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, demonstrated durable responses in patients with refractory LBCL in the pivotal phase 1/2 ZUMA-1 study (NCT02348216). Here, we compared SCHOLAR-1 with the 2-year outcomes of ZUMA-1. Prior to comparison of clinical outcomes, propensity scoring (based on a broad set of prognostic covariates) was used to create balance between ZUMA-1 and SCHOLAR-1 patients. In the pivotal phase 2 portion of ZUMA-1, 101 patients received axi-cel and were evaluable for response and survival. In SCHOLAR-1, 434 and 424 patients were evaluable for response and survival, respectively. ZUMA-1 patients were more heavily pretreated than were SCHOLAR-1 patients. The median follow-up was 27.1 months in ZUMA-1. The objective response rate (ORR) and complete response rate were 83% and 54% in ZUMA-1 vs 34% and 12% in SCHOLAR-1, respectively. The 2-year survival rate was 54% in ZUMA-1 and 20% in SCHOLAR-1, and a 73% reduction in the risk of death was observed in ZUMA-1 vs SCHOLAR-1. These results were consistent with those of an additional standardization analysis in which strata were limited to 2 prognostic factors (refractory categorization and presence/absence of stem cell transplant after refractoriness to chemotherapy) to conserve sample size. Despite the limitations of a nonrandomized analysis, these results indicate that axi-cel produces durable responses and a substantial survival benefit vs non–CAR T-cell salvage regimens for patients with refractory LBCL.
The Versatility of the DCIA Free Flap: A Forgotten Flap? Systematic Review and Meta-Analysis
Escandón, Joseph M. , Bustos, Valeria P. , Escandón, Lauren, Santamaría, Eric , Gaxiola-García, Miguel Ángel , Kushida-Contreras, Beatriz Hatsue , Forte, Antonio J. , Ciudad, Pedro , Langstein, Howard N. , Manrique, Oscar J. , Gaxiola-García, Miguel A , Kushida-Contreras, Beatriz H , Forte, Antonio Jorge , Escandón, Joseph M

Mayo Clinic

Journal of Reconstructive Microsurgery | August 28, 2021 | Volume: 38 | Issue: 05 | Pages: 378-389

10.1055/s-0041-1733978 | PMID 34454408 Get It

AbstractBackground Studies reporting on the deep circumflex iliac artery (DCIA) free flap are restricted to a limited number of patients and areas of application. The aim of this review was to assess the reliability and versatility of the DCIA free flap during reconstruction.Methods A comprehensive review was conducted in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) guidelines using PubMed, Web of Science, Cochrane CENTRAL, and SCOPUS. A critical analysis of pooled data was performed to assess outcomes employing the DCIA free flap.Results A total of 445 DCIA free flaps were included. The main recipient sites were head and neck (72.35%), lower extremity (20.67%), and upper extremity (6.74%). The main indications for reconstruction were tumor resection (73.8%) and trauma (17.43%). Fifty non-DCIA flaps were required to finalize the reconstruction of several defects. The pooled flap failure rate using the DCIA free flap was 4% (95% confidence interval: 1–8%). No significant heterogeneity was present across studies (Q statistic 22.12, p = 0.14; I 2 = 27.68%, p = 0.139). Complication rates for head and neck and limb reconstruction were 57.37 and 40.16%, respectively. The average length and surface area of bone flaps were 7.79 cm and 22.8 cm2, respectively. The area of the skin paddles was 117 cm2.Conclusion The DCIA free flap has shown to be a versatile reconstructive alternative for head and neck and short-medium size limb defects. However, the complexity of functions, the recipient site location, and a potential large defect can detract from the use of the DCIA free flap as an initial reconstructive option for head and neck and extensive limb defects.
Natural history and screening of interstitial lung disease in systemic autoimmune rheumatic disorders
Panagopoulos, P. , Goules, Andreas V. , Hoffmann‐Vold, Anna‐Maria , Matteson, Eric L. , Tzioufas, Athanasios G. , Panagopoulos, Panagiotis , Hoffmann-Vold, Anna-Maria

Mayo Clinic

Therapeutic Advances in Musculoskeletal Disease | August 28, 2021 | Volume: 13 | Issue: No issue available | Pages: No page available

10.1177/1759720x211037519 | PMID 34471427 Get It

Interstitial lung disease (ILD) is a relatively frequent manifestation of systemic autoimmune rheumatic disorders (SARDs), including systemic sclerosis (SSc), rheumatoid arthritis (RA), idiopathic inflammatory myopathies (IIM), systemic lupus erythematosus (SLE), primary Sjögren’s syndrome (pSS), and anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis. Interstitial pneumonia with autoimmune features (IPAF) has been proposed to describe patients with ILD who have clinical or serological findings compatible with SARDs but they are not sufficient for a definite diagnosis. ILD may present with different patterns among patients with SARDs, but most commonly as nonspecific interstitial pneumonia (NSIP), with the exception of RA and ANCA vasculitis that more often present with usual interstitial pneumonia (UIP). The natural history of ILD is quite variable, even among patients with the same SARD. It may present with subclinical features following a slow progressively course or with acute manifestations and clinically significant rapid progression leading to severe deterioration of pulmonary function and respiratory failure. The radiographic pattern of ILD, the extent of the disease, the baseline pulmonary function, the pulmonary function deterioration rate over time and clinical variables related to the primary SARD, such as age, sex and the clinical phenotype, are considered prognostic factors for SARDs-ILD associated with adverse outcomes and increased mortality. Different modalities can be employed for ILD detection including clinical evaluation, pulmonary function tests, high resolution computed tomography and novel techniques such as lung ultrasound and serum biomarkers. ILD may determine the clinical outcome of SARDs, since it is associated with significant morbidity and mortality and therefore screening of patients with SARDs for ILD is of great clinical importance.
Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphoma
Orellana‐Noia, Victor M. , Isaac, Krista M. , Malecek, Mary‐Kate , Bartlett, Nancy L. , Voorhees, Timothy , Grover, Natalie S. , Hwang, Steven R. , Bennani, N. Nora , Hu, Rachel , Hill, Brian T. , Mou, Eric , Advani, Ranjana H. , Carter, Jordan , David, Kevin A. , Ballard, Hatcher J. , Svoboda, Jakub , Churnetski, Michael C. , Magarelli, Gabriela, Feldman, Tatyana , Cohen, Jonathon B. , Evens, Andrew M. , Portell, Craig A. , Isaac, Krista , Voorhees, Timothy J , Cohen, Jonathon B , Bartlett, Nancy L , Advani, Ranjana H , Bennani, N Nora , Evens, Andrew M , Grover, Natalie S , Hwang, Steven R , Portell, Craig A , Mou, Eric

Mayo Clinic

Blood Advances | August 27, 2021 | Volume: 5 | Issue: 18 | Pages: 3623-3632

10.1182/bloodadvances.2021004645 | PMID 34448831 Get It

Abstract We performed a multicenter retrospective analysis across 10 US academic medical centers to evaluate treatment patterns and outcomes in patients age ≥60 years with classic Hodgkin lymphoma (cHL) from 2010-2018. Among 244 eligible patients, median age was 68, 63% had advanced stage (III/IV), 96% had Eastern Cooperative Oncology Group performance status (PS) 0-2, and 12% had documented loss of ≥1 activity of daily living (ADL). Medical comorbidities were assessed by the Cumulative Illness Rating Scale–Geriatric (CIRS-G), where n = 44 (18%) had total scores ≥10. Using multivariable Cox models, only ADL loss predicted shorter progression-free (PFS; hazard ratio [HR] 2.13, P = .007) and overall survival (OS; HR 2.52, P = .02). Most patients (n = 203, 83%) received conventional chemotherapy regimens, including doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD; 56%), AVD (14%), and AVD with brentuximab vedotin (BV; 9%). Compared to alternative therapies, conventional regimens significantly improved PFS (HR 0.46, P = .0007) and OS (HR 0.31, P = .0003). Survival was similar following conventional chemotherapy in those ages 60-69 vs ≥70: PFS HR 0.88, P = .63; OS HR 0.73, P = .55. Early treatment discontinuation due to toxicity was more common with CIRS-G ≥10 (28% vs 12%, P = .016) or documented geriatric syndrome (28% vs 13%, P = .02). A competing risk analysis demonstrated improved disease-related survival with conventional therapy (HR 0.29, P = .02) and higher mortality from causes other than disease or treatment with high CIRS-G or geriatric syndromes. This study suggests conventional chemotherapy regimens remain a standard of care in fit older patients with cHL, and highlights the importance of geriatric assessments in defining fitness for cHL therapy going forward.
Epidemiology, risk factors, and association of antifungal prophylaxis on early invasive fungal infection in heart transplant recipients
Yetmar, Zachary A. , Lahr, Brian D. , Brumble, Lisa , Gea‐Banacloche, Juan , Steidley, D. Eric , Kushwaha, Sudhir S. , Beam, Elena , Lahr, Brian , Kushwaha, Sudhir , Yetmar, Zachary A , Beam, Elena

Mayo Clinic

Transplant Infectious Disease | August 26, 2021 | Volume: 23 | Issue: 5 | Pages: No page available

10.1111/tid.13714 | PMID 34435415 Get It

Abstract Background Invasive fungal infection (IFI) in heart transplant recipients is associated with poor outcomes. Estimated risk of 1‐year IFI in heart transplant recipients is 3.4–8.6% with risk factors inconsistently identified in previous studies. The role of antifungal prophylaxis is unclear. The transplant program at Mayo Clinic provides 6 months of universal azole prophylaxis for those heart transplant recipients in Arizona. We sought to define risk factors for 1‐year IFI and determine the effect of antifungal prophylaxis. Methods We conducted a retrospective cohort study of patients undergoing heart transplantation at Mayo Clinic from January 2000 to March 2019. We analyzed demographics, details of transplant hospitalization, antifungal prophylaxis, and fungal infection. Multivariable Cox analyses were performed to identify risk factors of 1‐year IFI and impact of IFI on posttransplant mortality. Results A total of 966 heart transplant recipients were identified with a median age of 56 years (IQR 47, 62). A total of 444 patients received antifungal prophylaxis. Over 1‐year follow‐up, 62 patients developed IFI with a cumulative incidence of 6.4%. In multivariable analysis, factors associated with IFI were renal replacement therapy (RRT) (HR 3.24, 95% CI 1.65–6.39), allograft rejection (HR 2.33, 95% CI 1.25–4.34), and antifungal prophylaxis (HR 0.32, 95% CI 0.11–0.96). RRT was also associated with invasive mold infection (HR 3.00, 95% CI 1.29–6.97). Conclusions RRT and allograft rejection after transplantation are associated with 1‐year IFI, and RRT is also associated with invasive mold infection. Antifungal prophylaxis appears to be protective and further study is needed in the heart transplant population.
The interplay between gray matter and white matter neurodegeneration in subjective cognitive decline
Cedrés, Nira , Diaz‐Galvan, Patricia , Muehlboeck, J‐Sebastian, Barroso, José , Westman, Eric , Westman, Eric , Diaz-Galvan, Patricia , Díaz‐Flores, Lucio , Molina, Yaiza , Ferreira, Daniel

Mayo Clinic

Aging | August 25, 2021 | Volume: 13 | Issue: 16 | Pages: 19963-19977

10.18632/aging.203467 | PMID 34433132 Get It

Peripheral nerve block anesthesia/analgesia for patients undergoing primary hip and knee arthroplasty: recommendations from the International Consensus on Anesthesia-Related Outcomes after Surgery (ICAROS) group based on a systematic review and meta-analys
Memtsoudis, Stavros G. , Cozowicz, Crispiana , Bekeris, Janis, Bekere, Dace, Liu, Jiabin , Soffin, Ellen M. , Mariano, Edward R. , Johnson, Rebecca L. , Go, George , Hargett, Mary J. , Lee, Bradley H. , Wendel, Pamela , Brouillette, Mark , Kim, Sang Jo, Baaklini, Lila , Wetmore, Douglas S., Hong, Genewoo , Goto, Rie , Jivanelli, Bridget , Athanassoglou, Vassilis , Αrgyra, Eriphili, Barrington, Michael J. , Borgeat, Alain , El‐Boghdadly, Kariem , Elkassabany, Nabil , Gautier, Philippe , Gerner, Peter, Valle, Alejandro González Della , Goytizolo, Enrique A. , Guo, Zhenggang , Hogg, Rosemary , Kehlet, Henrik , Kessler, Paul, Lavand"homme, Patricia, Macfarlane, Alan , McIsaac, Dan , Neal, Joseph M. , Peng, Philip , Pichler, Lukas, Poultsides, Lazaros, Sites, Brian D. , Stundner, Ottokar , Sun, Eric, Viscusi, Eugene R. , Votta‐Velis, E. Gina, YaDeau, Jacques T. , Sharrock, Nigel E. , Barrington, Michael John , El-Boghdadly, K , Elkassabany, Nabil M , Kopp, Sandra , Mantilla, Carlos, Neal, Joseph M , Poeran, Jashvant , Schwenk, Eric S , Stundner, Ottokar , Viscusi, Eugene , Wu, Christopher L , Mariano, Edward R , Johnson, Rebecca L , Soffin, Ellen M , Macfarlane, Alan James Robert , Andrés, José De , Kessler, Paul, Kopp, Sandra L. , Lavand"homme, Patricia, MacLean, Catherine H. , Mantilla, Carlos B. , McLawhorn, Alexander S. , Parks, Michael L. , Parvizi, Javad , Schwenk, Eric S.

Mayo Clinic

Regional Anesthesia & Pain Medicine | August 25, 2021 | Volume: 46 | Issue: 11 | Pages: 971-985

10.1136/rapm-2021-102750 | PMID 34433647 Get It

Background Evidence-based international expert consensus regarding the impact of peripheral nerve block (PNB) use in total hip/knee arthroplasty surgery. Methods A systematic review and meta-analysis: randomized controlled and observational studies investigating the impact of PNB utilization on major complications, including mortality, cardiac, pulmonary, gastrointestinal, renal, thromboembolic, neurologic, infectious, and bleeding complications. Medline, PubMed, Embase, and Cochrane Library including Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, NHS Economic Evaluation Database, were queried from 1946 to August 4, 2020. The Grading of Recommendations Assessment, Development, and Evaluation approach was used to assess evidence quality and for the development of recommendations. Results Analysis of 122 studies revealed that PNB use (compared with no use) was associated with lower ORs for (OR with 95% CIs) for numerous complications (total hip and knee arthroplasties (THA/TKA), respectively): cognitive dysfunction (OR 0.30, 95% CI 0.17 to 0.53/OR 0.52, 95% CI 0.34 to 0.80), respiratory failure (OR 0.36, 95% CI 0.17 to 0.74/OR 0.37, 95% CI 0.18 to 0.75), cardiac complications (OR 0.84, 95% CI 0.76 to 0.93/OR 0.83, 95% CI 0.79 to 0.86), surgical site infections (OR 0.55 95% CI 0.47 to 0.64/OR 0.86 95% CI 0.80 to 0.91), thromboembolism (OR 0.74, 95% CI 0.58 to 0.96/OR 0.90, 95% CI 0.84 to 0.96) and blood transfusion (OR 0.84, 95% CI 0.83 to 0.86/OR 0.91, 95% CI 0.90 to 0.92). Conclusions Based on the current body of evidence, the consensus group recommends PNB use in THA/TKA for improved outcomes. Recommendation: PNB use is recommended for patients undergoing THA and TKA except when contraindications preclude their use. Furthermore, the alignment of provider skills and practice location resources needs to be ensured. Evidence level: moderate; recommendation: strong.
TOP2B Enzymatic Activity on Promoters and Introns Modulates Multiple Oncogenes in Human Gliomas
González-Buendía, Edgar , Zhao, Junfei , Mukherjee, Subhas, Zhang, Daniel Y. , Feldstein, Eric , Kang, Seong Jae , Lee-Chang, Catalina , Mahajan, Aayushi , Chen, Li , Karan, Charles , Magnuson, Lisa, Marshall, Stacy A. , Mohyeldin, Ahmed, Nakano, Ichiro , Bansal, Mukesh , James, C. David , Ahmed, Atique U. , Canoll, Peter , Shilatifard, Ali , Zhang, Daniel , Realubit, Ronald , Karan, Charles , Ahmed, Atique , Sonabend, Adam M , Wang, Lu , Mukherjee, Subhas, Arrieta, Victor Andrés , KANE, JOSHUA ROBERT , Horbinski, Craig , Sarkaria, Jann N. , Brat, Daniel J. , Rabadán, Raúl

Mayo Clinic

Clinical Cancer Research | August 25, 2021 | Volume: 27 | Issue: 20 | Pages: 5669-5680

10.1158/1078-0432.ccr-21-0312 | PMID 34433651 Get It

Abstract Purpose: The epigenetic mechanisms involved in transcriptional regulation leading to malignant phenotype in gliomas remains poorly understood. Topoisomerase IIB (TOP2B), an enzyme that decoils and releases torsional forces in DNA, is overexpressed in a subset of gliomas. Therefore, we investigated its role in epigenetic regulation in these tumors. Experimental Design: To investigate the role of TOP2B in epigenetic regulation in gliomas, we performed paired chromatin immunoprecipitation sequencing for TOP2B and RNA-sequencing analysis of glioma cell lines with and without TOP2B inhibition and in human glioma specimens. These experiments were complemented with assay for transposase-accessible chromatin using sequencing, gene silencing, and mouse xenograft experiments to investigate the function of TOP2B and its role in glioma phenotypes. Results: We discovered that TOP2B modulates transcription of multiple oncogenes in human gliomas. TOP2B regulated transcription only at sites where it was enzymatically active, but not at all native binding sites. In particular, TOP2B activity localized in enhancers, promoters, and introns of PDGFRA and MYC, facilitating their expression. TOP2B levels and genomic localization was associated with PDGFRA and MYC expression across glioma specimens, which was not seen in nontumoral human brain tissue. In vivo, TOP2B knockdown of human glioma intracranial implants prolonged survival and downregulated PDGFRA. Conclusions: Our results indicate that TOP2B activity exerts a pleiotropic role in transcriptional regulation of oncogenes in a subset of gliomas promoting a proliferative phenotype.
Credibility assessment of patient-specific biomechanical models to investigate proximal junctional failure in clinical cases with adult spine deformity using ASME V&V40 standard
Poncelas, Maeva Lopez , Barbera, Luigi La , Rawlinson, Jeremy , Crandall, Dennis G. , Aubin, Carl‐Éric , Lopez Poncelas, M , La Barbera, L , Rawlinson, J J , Crandall, D , Aubin, C E

Mayo Clinic

Computer Methods in Biomechanics and Biomedical Engineering | August 24, 2021 | Volume: 25 | Issue: 5 | Pages: 543-553

10.1080/10255842.2021.1968380 | PMID 34427119 Get It